Progressive-Medical-Development near St. Clements MB (7 Result(s))

Wound Biofilm© MSU-CBE, all rights reservedKane Biotech Inc. is dedicated to the research and development of products to prevent and disperse microbial biofilms. The Company was formed in 2001 and is developing products for the prevention and dispersal of biofilms focused on the genetic mechanisms of biofilm formation, and originally based upon the discovery of over 60 novel anti-biofilm targets. Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.Biofilms are estimated to be responsible for 80% of all human infections and cost industry, cities and hospitals in excess of $500 billion each year.Kane Biotech has a growing pipeline of products based on the Company's ability to screen for factors affecting biofilm formation and has resulted in the development of candidate products based on the demand for safe and effective anti-biofilm compounds.VisionTo become a global leader in creating innovative technology to breakdown and disperse biofilms and to develop unique products that have a positive impact on human health

IMRIS provides an optimized fully integrated image guided therapy environment in a unique hybrid OR that delivers timely information on surgical targets and results to clinicians for use during surgical or interventional procedures. The VISIUS Surgical Theatre incorporates magnetic resonance imaging (MRI), CT and fluoroscopy into multi-purpose surgical suites to provide truly intraoperative imaging for specific medical applications by bringing advanced imaging into the OR. Our products are sold globally to hospitals that deliver clinical services to patients in the neurosurgical, interventional, and orthopedic markets.The VISIUS Surgical Theatre is designed to address the important needs of patients, clinicians and hospitals.PatientsPeer reviewed and published data show the degree of tumor resection is increased in the VISIUS Surgical Theatre because residual tumor is found during intraoperative imaging. More complete tumor removal means increased survival and reduced re-operation rates.

Saving Lives Through Early Disease DiagnosisMiraculins is an emerging biotechnology company committed to extending life, reducing suffering and lowering healthcare costs. Through our leadership in the development and commercialization of diagnostic tests, we strive to improve the overall diagnosis and treatment of patients by enhancing the information available to physicians.The Miraculins AdvantageProducts & ProgramsMiraculins is dedicated to the development and commercialization of diagnostic tests and risk assessment technologies for diseases and conditions that are lacking highly sensitive and specific tests.